This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Johannesson, M. Articles by O'Conor, R. M. Search for Related Content PubMed PubMed Citation Articles by Johannesson, M. Articles by O'Conor, R. M. Social Bookmarking                         What's this?

Incorporating Future Costs in Medical Cost-Effectiveness Analysis

Implications for the Cost-Effectiveness of the Treatment of Hypertension

David Meltzer, MD, PhD

Richard M. O'Conor, PhD

It has been shown that the difference between consumption and production during life years gained should be included as a cost in cost-effectiveness analysis. In this study the authors estimate the impact of including these future costs on the cost-effective ness of the treatment of hypertension in Sweden. The cost per quality-adjusted life year (QALY) gained changes little among young men and women due to the addition of future costs, but increases by about $14,000 for middle-aged men and women and about $27,000 for older men and women. When future costs are not included, the cost per QALY gained is generally lowest among older men and women, but when future costs are included, the cost per QALY gained is generally lowest among middle-aged men and women. The authors conclude that the total resource consequences of changes in mortality should be routinely considered in cost-effectiveness analyses. Key words: Cost-effectiveness analysis; economic evaluation; costs; societal per spective. (Med Decis Making 1997;17:382-389)

Medical Decision Making, Vol. 17, No. 4, 382-389 (1997)
DOI: 10.1177/0272989X9701700403


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Lidgren, B. Jonsson, C. Rehnberg, N. Willking, and J. Bergh Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer Ann. Onc., March 1, 2008; 19(3): 487 - 495. [Abstract] [Full Text] [PDF]

				P Lindgren, M Buxton, T Kahan, N R Poulter, B Dahlof, P S Sever, H Wedel, B Jonsson, and on behalf of the ASCOT trial investigators* Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen Heart, February 1, 2008; 94(2): e4 - e4. [Abstract] [Full Text] [PDF]

				P. Lindgren, J. Graff, A. G. Olsson, T. J. Pedersen, B. Jonsson, and on behalf of the IDEAL Trial Investigators Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Eur. Heart J., June 2, 2007; 28(12): 1448 - 1453. [Abstract] [Full Text] [PDF]

				P. E. Lonning Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer Ann. Onc., February 1, 2006; 17(2): 217 - 225. [Abstract] [Full Text] [PDF]

				References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]

				M Johannesson At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur. Heart J., June 1, 2001; 22(11): 919 - 925. [Abstract] [PDF]

				T. O. Tengs, M. Yu, E. Luistro, and H. B. Bosworth Health-Related Quality of Life After Stroke A Comprehensive Review Editorial Comment : Health-Related Quality Of Life After Stroke: A Comprehensive Review Stroke, April 1, 2001; 32(4): 964 - 972. [Abstract] [Full Text] [PDF]

				B Almbrand, M Johannesson, B Sjostrand, K Malmberg, and L Ryden Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus. Results from the DIGAMI study Eur. Heart J., May 1, 2000; 21(9): 733 - 739. [Abstract] [PDF]

				L. C. Immergluck, W. L. Cull, A. Schwartz, and A. S. Elstein Cost-Effectiveness of Universal Compared With Voluntary Screening for Human Immunodeficiency Virus Among Pregnant Women in Chicago Pediatrics, April 1, 2000; 105(4): 54e - 54. [Abstract] [Full Text]

				D. Meltzer and M. Johannesson Inconsistencies in the "Societal Perspective" on Costs of the Panel on Cost-Effectiveness in Health and Medicine Med Decis Making, October 1, 1999; 19(4): 371 - 377. [Abstract] [PDF]